[ad_1] A recent trial sought to badess the effect of palbociclib on overall survival (OS) and the efficacy of subsequent therapy in patients with hormone receptor-positive (HR +), HER2-negative advanced bad cancer. …
Read More »Palbociclib Plus Fulvestrant Increases OS in HR +, HER2-Negative Breast Cancer
